Your search for upadacitinib returned 49 results

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of July. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of May. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

Upadacitinib 15mg, 30mg, 45mg; ext-rel tabs.

The approval was based on studies that included adults with moderately to severely active Crohn disease who had an inadequate response to or were intolerant of biologic therapy.

Researchers assessed the effects of upadacitinib 45 mg once daily within the first 15 days of treatment in patients with Crohn disease.

Researchers examined risk for herpes zoster infection with biologics and small molecules for IBD.

The analysis included 140 patients from the SELECT-BEYOND cohort and 258 patients from the SELECT-CHOICE cohort.

The patient cohorts were well-balanced at baseline, and, overall, 45.4% had a history of biologic therapy failure.

The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy.

The application is supported by data from the two phase 3 induction studies, U-EXCEED and U-EXCEL, and one phase 3 maintenance study, U-ENDURE.